|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Sanjiv Agarwala, MD, from St. Luke’s Cancer Center in Bethlehem, Pennsylvania, and Vernon Sondak, MD, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, discusses the topic of melanoma focusing on the following data releases:
#4: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
#8509: Re-induction with ipilimumab, gp100 peptide vaccine, or a
combination of both from a phase III, randomized, double-blind,
multicenter study of previously treated patients with unresectable stage
III or IV melanoma
#8504: E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma
#LBA8512: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma
|
| |
|
 View an expert interview and opinion with Sanjiv Agarwala, MD, and Vernon Sondak, MD.
Click here to complete the post-test online |
|
|
|
|
|
|
